GRCE (Grace Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


GRCE Grace Therapeutics Inc GRCE
31 GF Score
Price $2.33
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics FCF Margin %?

Grace Therapeutics GRCE -2.71% 31 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates GRCE with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, Grace Therapeutics ranks worse than 104166.56% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Grace Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-1.70 Mil. Grace Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Grace Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Grace Therapeutics's current FCF Yield % is -23.44%.

The historical rank and industry rank for Grace Therapeutics's FCF Margin % or its related term are showing as below:


During the past 13 years, the highest FCF Margin % of Grace Therapeutics was -7340.82%. The lowest was -7340.82%. And the median was -7340.82%.

GRCE's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -85.21
* Ranked among companies with meaningful FCF Margin % only.

Grace Therapeutics FCF Margin % Related Terms

Grace Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Grace Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grace Therapeutics FCF Margin % Chart

Grace Therapeutics Annual Data
Trend Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Grace Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GRCE vs PSTV, ATNM, NNVC: FCF Margin % Comparison

For the Biotechnology subindustry, Grace Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grace Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Grace Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Grace Therapeutics's FCF Margin % falls into.


GRCE
31GF Score
Grace Therapeutics Inc GRCE
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Grace Therapeutics's FCF Margin for the fiscal year that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-8.869/0
= %

Grace Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.695/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Grace Therapeutics (GRCE) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Grace Therapeutics and its competitors. According to the industry distribution chart, Grace Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry.
Is Grace Therapeutics' FCF Margin % too high?
Grace Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Grace Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' FCF Margin % compare to PSTV and ATNM?
According to the Biotechnology industry distribution chart, Grace Therapeutics ranks #999999 out of 960 companies for FCF Margin %. This places Grace Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Grace Therapeutics and its competitors. Grace Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grace Therapeutics Business Description

Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score

Get the complete analysis for GRCE

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.33
Price